99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer
Condition: Breast Cancer Intervention: Drug: 99mTc-HPArk2 Sponsor: Peking Union Medical College Hospital Recruiting
Conclusions99mTc-HYNIC-H10F specifically accumulates in HER2-positive tumors. Compared with trastuzumab,99mTc-HYNIC-H10F binds to a different domain of HER2 antigen, providing new opportunities to monitor HER2 expression levels before/during/after trastuzumab treatment for more effective personalized treatment.
Condition: Primary Breast Cancer Intervention: Diagnostic Test: SPECT Sponsors: Tomsk National Research Medical Center of the Russian Academy of Sciences; Institute of Bioorganic Chemistry, Russian Academy of Sciences; Uppsala University Enrolling by invitation
In this study, an intermediate (compound 3), which could be hydrolyzed into the ligand (compound L) consisting of palbociclib as the bioactive molecule and 6-hydrazino nicotinamide (HYNIC) as the bifunctional chelator, was synthesized. Compound L was radiolabeled with 99mTc using tricine/TPPTS or tricine/TPPMS as co-ligands. 99mTc-tricine-TPPTS-L and 99mTc-tricine-TPPMS-L were prepared with high radiochemical purity without postlabeling purification. They had great in vitro stability. Both radiotracers were hydrophilic, but 99mTc-tricine-TPPTS-L had a lower log P value. In vitro cell uptake studies in MCF-7 ...